Could a Low-Dose immune therapy restore hair in severe alopecia?

NCT ID NCT02557074

Completed Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether low doses of interleukin-2 (IL2) can help people with severe alopecia areata, a condition causing patchy or total hair loss. 44 adults with at least 50% scalp hair loss who had not responded to other treatments received either IL2 injections or a placebo. The main goal was to see if hair regrowth reached a certain level (SALT score ≤25) after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-dose interleukin-2 (IL2)
What this could lead to: If it works, this could provide a new treatment option for people with severe alopecia areata who haven't responded to other therapies.
What could go wrong: This is a small Phase 3 trial with only 44 participants, so results may not apply to everyone. The treatment involves injections and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

AP-HM - La timone - Dermatologie

Marseille, Bouche Du Rhône, 13005, France
AP-HP St Louis - Dermatologie

Paris, Île-de-France Region, 75000, France
CHI St Raphael Fréjus - Dermatologie

Fréjus, PACA, 83000, France
CHU Montpellier - Dermatologie

Montpellier, 34000, France
CHU de Nice - dermatologie

Nice, 06200, France
CHU de Nimes - Dermatologie

Nîmes, Languedoc-Roussillon, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.